4//SEC Filing
HIRSCH RUSSELL C 4
Accession 0001209191-13-029628
CIK 0001269021other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 4:45 PM ET
Size
30.9 KB
Accession
0001209191-13-029628
Insider Transaction Report
Form 4
HIRSCH RUSSELL C
Director
Transactions
- Conversion
Common Stock
2013-05-28+27,237→ 27,237 total(indirect: Prospect Associates II, L.P.) - Conversion
Common Stock
2013-05-28+1,788,647→ 1,788,647 total(indirect: Prospect Venture Partners II, L.P.) - Conversion
Series D Preferred Stock
2013-05-28−106,114→ 0 total(indirect: Prospect Venture Partners II, L.P.)→ Common Stock (106,114 underlying) - Conversion
Series A Preferred Stock
2013-05-28−956,029→ 0 total(indirect: Prospect Venture Partners II, L.P.)→ Common Stock (956,029 underlying) - Conversion
Series B Preferred Stock
2013-05-28−353,839→ 0 total(indirect: Prospect Venture Partners II, L.P.)→ Common Stock (353,839 underlying) - Conversion
Series C Preferred Stock
2013-05-28−372,665→ 0 total(indirect: Prospect Venture Partners II, L.P.)→ Common Stock (372,665 underlying) - Conversion
Series D Preferred Stock
2013-05-28−1,616→ 0 total(indirect: Prospect Associates II, L.P.)→ Common Stock (1,616 underlying) - Conversion
Series A Preferred Stock
2013-05-28−14,558→ 0 total(indirect: Prospect Associates II, L.P.)→ Common Stock (14,558 underlying) - Conversion
Series B Preferred Stock
2013-05-28−5,388→ 0 total(indirect: Prospect Associates II, L.P.)→ Common Stock (5,388 underlying) - Conversion
Series C Preferred Stock
2013-05-28−5,675→ 0 total(indirect: Prospect Associates II, L.P.)→ Common Stock (5,675 underlying)
Footnotes (7)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- [F2]Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- [F3]Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- [F4]Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- [F5]The shares are owned by PA II, which is under common control with PVP II. PMC II serves as the sole general partner of PA II. The Reporting Person is a Managing Director of PMC II. As such, the Reporting Person shares voting and investment power over the shares held by PA II and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
- [F6]The shares are owned by Prospect Venture Partners II, L.P. ("PVP II"), which is under common control with Prospect Associates II, L.P. ("PA II"). Prospect Management Co. II, L.L.C. ("PMC II") serves as the sole general partner of PVP II. The Reporting Person is a Managing Director of PMC II. As such, the Reporting Person shares voting and investment power over the shares held by PVP II and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
- [F7]The shares do not have an expiration date.
Issuer
PORTOLA PHARMACEUTICALS INC
CIK 0001269021
Entity typeother
Related Parties
1- filerCIK 0001162059
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 4:45 PM ET
- Size
- 30.9 KB